Company Profile for Prevendia, Inc.

--(BUSINESS WIRE)--Prevendia Inc. is an innovative medical diagnostic company offering a revolutionary solution to determine a patient’s insulin resistance (IR) level by analyzing a small blood sample and reporting the results. This testing is significant because IR is a silent condition that is an early predictor of serious chronic diseases such as type 2 diabetes (T2D) and cardiovascular disease (CVD). Additionally, clinical studies implicate IR as a precursor to infertility, obesity, sub-clinical inflammation, micro-vascular disease, hypertension, certain cancers and Alzheimer’s disease. When diagnosed, IR progression can be slowed, stopped or reversed by appropriate insulin sensitizing interventions. Prevendia’s clinical diagnostic solution is ideal for prenatal care, pediatrics, cardiovascular, infertility and corporate wellness programs.

Offering a highly cost-effective, accurate and reproducible method for diagnosing IR, Prevendia eliminates the onerous patient responsibilities required by current tests. Prevendia uses proprietary sample processing techniques and software algorithms to determine a patient’s IR status by comparing the infrared spectrum of the sample to a database of normal patient spectra. The Prevendia solution employs proven off-the-shelf instrumentation components coupled with multivariate analysis software algorithms. Independent market research indicates a domestic market potential of 100 million tests annually. Prevendia is a privately held company located in Mountain View, CA. For more information contact info@prevendia.com.

Company:		Prevendia, Inc.
Headquarters Address:		156 Preston Drive
		Mt. View, CA 94040
Main Telephone:		650-208-3081
Website:		www.prevendia.com
Type of Organization:		Private
		PR
Industry:		Biotechnology
Key Executives:		CEO: Mark Koester
Public Relations
Contact:		Kristi Furrer
Phone:		303-525-0924
Email:		kristi@goldenimpressions.com